STAT3 and glioma: Furthermore, based on available specimens, there was a trend in the increase of glioma p-STAT3 expression to a mean of 35.5 + 10.3% at recurrence in the bevacizumab-treated patients relative to the original, pre-treatment matched specimens that had a mean of 14.8 + 7.6% p-STAT3 expressing cells (P= 0.08 by student t-test) (Supplementary Figure 1).